Physician profile
Jasbir Kaur
NPI 1912584608
$2,123.30
in general payments reported to CMS, 2019-2025
27 companies · $1,714 in 2025
The $1,714 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $14.03 · 2024: $270 · 2025: $1,714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,913 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,913.31 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $403.26 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $223.32 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $169.40 | 2025 | |
| Lilly USA, LLC | $166.39 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $123.95 | 2025 | |
| Abbvie INC. | $119.97 | 2025 | |
| Astellas Pharma US INC | $113.62 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.61 | 2025 | Ofev, Jardiance |
| Gilead Sciences, INC. | $63.76 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.77 | 2025 | |
| Exact Sciences Corporation | $58.63 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $56.32 | 2025 | Sapien 3 Ultra Resilia |
| Inspire Medical Systems, INC. | $47.92 | 2025 | Inspire |
| Sumitomo Pharma America, INC. | $47.59 | 2024-2025 | Gemtesa |
| Boston Scientific Corporation | $43.49 | 2025 | General - Pain Management |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $40.38 | 2024-2025 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $38.52 | 2024-2025 | Heplisav-B |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.94 | 2024-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $33.44 | 2025 | Arexvy, Shingrix |
| Amgen INC. | $32.99 | 2024-2025 | Evenity, Prolia |
| Biogen, INC. | $26.81 | 2025 | Leqembi |
| Viiv Healthcare Company | $26.70 | 2025 | Apretude |
| Calliditas Therapeutics US INC. | $24.67 | 2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $23.78 | 2025 | |
| Vivus LLC | $18.21 | 2024 | Qsymia |
| Agios Pharmaceuticals, INC. | $17.53 | 2025 | Pyrukynd |
| Merck Sharp & Dohme LLC | $17.33 | 2024 | Gardasil 9, Gardasil, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasbir Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.